DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES)

Information source: University Hospital, Antwerp
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Non-Small Cell Lung Cancer

Intervention: cisplatin + docetaxel (Drug); cisplatin + docetaxel + enoxaparin (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: University Hospital, Antwerp

Official(s) and/or principal investigator(s):
Paul R Germonpre, MD PhD, Principal Investigator, Affiliation: Universiteit Antwerpen

Summary

Rationale: a number of recent phase III randomized trials have shown a survival benefit of a treatment with subcutaneous low-molecular weight heparin in patients with advanced solid malignancies. The survival advantages observed in the studies persist for months after the active treatment with LMWHs. Therefore these survival advantages are thought to be due to effects of LMWHs on tumor cell biology. First line treatment of advanced NSCLC patients with the Cisplatin + Docetaxel combination has been widely studied, and is amongst the most active treatments currently available. The occurrence of grade 3/4 thrombopenia in several phase III trials was in the 0-3% range, making it an ideal chemotherapy regimen to combine with LMWHs in the treatment of advanced NSCLC.

Clinical Details

Official title: Low Molecular Weight Heparin in Advanced Non Small Cell Lung Cancer (NSCLC): a Randomized Open Label Phase III Study Evaluating the Effect of Enoxaparin (Clexane) on Survival and Symptom Control in Patients With Stage IIIB and IV NSCLC Undergoing a Cisplatin Based First Line Chemotherapy: the SYRINGES Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Progression Free Survival

Secondary outcome:

Symptom control evaluated with the Lung Cancer Symptoms Scale (LCSS)

Overall Survival

Best Overall Response

Incidence of total documented thromboembolic and hemorrhagic events

Overall safety and tolerability

Detailed description: Purpose: the aim of this study is to evaluate the potential beneficial antitumoral effect of LMWH enoxaparin in patients with locally advanced or metastatic NSCLC determined by the time to progression, the overall survival and the symptom control. LMWH will be added to a first line cisplatin-based chemotherapy.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Locally advanced or metastatic NSCLC (stage IIIB or IV)

- Patients who are not candidates for radical combined modality treatments or high-dose

radiation therapy

- At least one measurable lesion according to RECIST criteria

- Good performance status

- Adequate haematological, renal and liver function

- Written informed consent

Exclusion Criteria:

- Previous chemotherapy for NSCLC

- Brain metastasis

- History of cerebral haemorrhage, neurosurgery within 3 previous months or surgery

within the past 6 months

- Indication for anticoagulant therapy, thrombolytic therapy or antiplatelet therapy

for cardiovascular disease

- Concomitant therapy with an anti-angiogenesis agent

- Contra-indication for LMWH

- Life expectancy of < 3 months

- Serious concomitant systemic disease, uncontrolled arterial hypertension, active

peptic ulcer or other condition which does not permit study treatment or follow-up required to comply with the study protocol

Locations and Contacts

Centre Hospitalier Universitaire Sart Tilman, Li├Ęge 4000, Belgium

University Hospital Antwerp, Edegem, Antwerp 2650, Belgium

Additional Information

Starting date: June 2008
Last updated: June 27, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017